Clinical Trials

Lung Microbiota and Inflammatory Response in Cystic Fibrosis (CF)

Purpose

The purpose of this study is to evaluate microbiomes in the upper and lower respiratory tract. Micobiomes are different bacteria that can be identified using advanced technologies that identify the genetic components of the bacteria. If you have cystic fibrosis or are a patient of the pediatric pulmonary division that is having a procedure called a bronchoscopy and are interested in learning more of this study please contact the study coordinator, Dawn Baker, ARNP or call (352) 273-8381.

Forms

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) (START-Too)

Purpose

The purpose of this study is to compare two methods of treatment against new aquisition of Methicillin-resistant Staphylococcus Aureus (MRSA) in Cystic Fibrosis (CF).If you are interested in learning more of this study please contact the study coordinator, Dawn Baker, ARNP or call (352) 273-8381.

Subjects

  • Ages 4 to 45 with Cystic Fibrosis
  • New acquisition of MRSA in the past 6 months
  • Must NOT have taken antibiotics with activity against MRSA in the past month
  • Tolerant to TMP/SMX, rifampin, or minocyline

Forms

 

Evaluation of a combination of two asthma drugs

Your child may be eligible to participate in a 6-month study evaluating a combination of two asthma drugs. The study involves 6 visits, each about two hours long.

Forms

 

Pilot study comparing airway responsiveness to two doses of medication

Your child may be eligible to participate in a research study evaluating different doses of a currently marketed combination medication. The study involves 3-4 visits, each about 2 hours long.

Forms